The global HER2 negative breast cancer market is experiencing dynamic expansion, propelled by the urgent need for more effective and less toxic treatments This category, which includes the majority of all breast cancer diagnoses, necessitates continuous innovation to address the vast and varied therapeutic needs of the patient population The driving force behind this market...